NewsRx

Search our medical news database

Angina

Gene transfer yields favorable results in cardiac trial

Published in Gene Therapy Weekly, May 16th, 2002

by Sonia Nichols, senior medical writer - Gene therapy could lead the way for providing relief to patients who suffer from stable angina pectoris.

The initial results of a double-blind, randomized trial of 79 patients participating in the multicenter angiogenic gene therapy (AGENT) trial have indicated viral-based therapy delivering genes for fibroblast growth factor (FGF) directly to the heart improves exercise time on treadmill tests in patients with angina.

The study cohort included angina patients categorized as class 2 or 3 under the Canadian Cardiovascular Society classification system. Cindy L. Grines and colleagues at William Beaumont...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook